medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2021, Number 1

<< Back Next >>

Arch Neurocien 2021; 26 (1)

Guillain-Barré syndrome associated with SARS-CoV-2 infection: A case report in Mexico

Bravo-Armenta E, Uc-Miam ME, Ramos-Xochihua LM, Gamboa-Solis E, Avendaño-Venegas R

Language: Spanish
References: 11
Page: 43-48
PDF size: 330.21 Kb.


ABSTRACT

In December 2019, the first cases of COVID-19 were reported in Wuhan, China. Up to now, it has affected over 60 million people worldwide. COVID-19 is a multi-systemic disease; in addition to respiratory manifestations, various neurological complications have been identified, including encephalitis, stroke, and Guillain-Barré syndrome. Guillain-Barré syndrome is a condition of immunemediated polyneuropathies frequently associated with infections. We present the case of a 41-year-old man that, after a 5-day history of non-productive cough, headache, muscle pain, joint pain, anosmia, ageusia, and non-quantified temperature rise; developed loss of tendon flexes and lower limbs weakness that progressed to walking disability, upper limbs weakness, and bilateral facial paresis. An oropharyngeal swab polymerase chain reaction confirmed SARS-CoV-2 infection, and the cerebrospinal analysis reported albuminocytologic dissociation. Nerve conduction studies showed acute inflammatory demyelinating polyradiculoneuropathy (AIDP). He received a 5-day course of intravenous immune globulin. There have been numerous reports of Guillain-Barré syndrome associated with SARS-CoV-2 infection worldwide; however, few cases have been reported in Latin America.


REFERENCES

  1. Yuki N, Hartung HP. Guillain-Barré syndrome. The New England J Med. 2012; 366(24), 2294–2304. DOI: 10.1056/ NEJMra1114525

  2. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurol. 2008; 70(18), 1608–1613. DOI: 10.1212/01. wnl.0000310983.38724.d4

  3. Wakerley BR, Yuki N. Infectious and noninfectious triggers in Guillain- Barré syndrome. Expert Rev Clin Immunol. 2013; 9(7):627- 639.DOI: https://doi.org/10.1586/1744666X.2013.811119

  4. Dalakas MC. Guillain-Barre syndrome: The first documented COVID- 19-triggered autoimmune neurologic disease: MORE to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020; 7 (5) e781. DOI: 10.1212/NXI.0000000000000781

  5. Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. Acta Neurol Scand. 2020; 142(1):14-22 DOI:10.1111/ane.13266

  6. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(3):767-783. DOI:10.1016/S1474-4422(20)30221-0

  7. Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2020; 25;1-38 DOI: 10.1007/s00415-020-10124-x

  8. Webb S, Wallace V, Martin-Lopez D, Yogarajah M. Guillain- Barré syndrome following COVID-19: a newly emerging postinfectious complication BMJ Case Rep. 2020; 13(6):1-4 DOI: 10.1136/bcr-2020-236182

  9. Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: Where do we stand? Clin Neurophysiol. 2018 Dec;129(12):2586-2593 DOI: 10.1016/j.clinph.2018.09.025

  10. Rajabally YA, Uncini A. Outcome and its predictors in Guillain Barre syndrome. J Neurol Neurosurg Psychiatry. 2012; 83(7):711- 8 DOI: 10.1136/jnnp-2011-301882

  11. Needham EJ, Chou SH, Coles AJ, Menon DK. Neurological Implications of COVID-19 Infections. Neurocrit Care. 2020; 32(3):667-671. DOI: 10.1007/s12028-020-00978-4




2020     |     www.medigraphic.com